148 related articles for article (PubMed ID: 36517590)
1. EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Yu T; Zhou F; Tian W; Xu R; Wang B; Zeng A; Zhou Z; Li M; Wang Y; Zhang J
Oncogene; 2023 Feb; 42(6):461-470. PubMed ID: 36517590
[TBL] [Abstract][Full Text] [Related]
2. Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma.
Pang F; Zhang L; Li M; Yi X; Wang Y; Yang P; Wen B; Jiang J; Teng Y; Yang X; Chen L; Xu J; Wang L
Cancer Gene Ther; 2023 Dec; 30(12):1636-1648. PubMed ID: 37726387
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma stem cells deliver ABCB4 transcribed by ATF3 via exosomes conferring glioblastoma resistance to temozolomide.
Xu X; Zheng Y; Luo L; You Z; Chen H; Wang J; Zhang F; Liu Y; Ke Y
Cell Death Dis; 2024 May; 15(5):318. PubMed ID: 38710703
[TBL] [Abstract][Full Text] [Related]
4. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Stazi G; Taglieri L; Nicolai A; Romanelli A; Fioravanti R; Morrone S; Sabatino M; Ragno R; Taurone S; Nebbioso M; Carletti R; Artico M; Valente S; Scarpa S; Mai A
Clin Epigenetics; 2019 Dec; 11(1):173. PubMed ID: 31791385
[TBL] [Abstract][Full Text] [Related]
6. Interplay of m
Li F; Chen S; Yu J; Gao Z; Sun Z; Yi Y; Long T; Zhang C; Li Y; Pan Y; Qin C; Long W; Liu Q; Zhao W
Clin Transl Med; 2021 Sep; 11(9):e553. PubMed ID: 34586728
[TBL] [Abstract][Full Text] [Related]
7. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
8. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
9. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
10. TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temozolomide Resistance.
Li Y; Wang T; Wan Q; Wang Q; Chen Z; Gao Y; Ye Y; Lin J; Zhao B; Wang H; Yang J; Zhao K; Lu N
Cancer Res; 2022 Oct; 82(19):3573-3587. PubMed ID: 35895752
[TBL] [Abstract][Full Text] [Related]
11. UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway.
Wang Y; Gao G; Wei X; Zhang Y; Yu J
Drug Des Devel Ther; 2023; 17():1357-1369. PubMed ID: 37181827
[TBL] [Abstract][Full Text] [Related]
12. EZH2 regulates the malignancy of human glioblastoma cells via modulation of Twist mRNA stability.
Zhai X; Li LS; Zhou YD; Ji WY; Chen H; Xiao H; Liang P
Eur J Pharmacol; 2021 Aug; 904():174177. PubMed ID: 34015321
[TBL] [Abstract][Full Text] [Related]
13. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
14. EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide.
Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J
Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167
[TBL] [Abstract][Full Text] [Related]
15. LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p/MAP3K1 axis.
Bi CL; Liu JF; Zhang MY; Lan S; Yang ZY; Fang JS
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33057597
[TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
Yin J; Ge X; Shi Z; Yu C; Lu C; Wei Y; Zeng A; Wang X; Yan W; Zhang J; You Y
Theranostics; 2021; 11(4):1763-1779. PubMed ID: 33408780
[No Abstract] [Full Text] [Related]
17. Long intergenic noncoding RNA 00021 promotes glioblastoma temozolomide resistance by epigenetically silencing p21 through Notch pathway.
Zhang S; Guo S; Liang C; Lian M
IUBMB Life; 2020 Aug; 72(8):1747-1756. PubMed ID: 32449315
[TBL] [Abstract][Full Text] [Related]
18. LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt/β-catenin signaling.
Lu Y; Tian M; Liu J; Wang K
J Biochem Mol Toxicol; 2021 Sep; 35(9):e22848. PubMed ID: 34328678
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Tomar VS; Patil V; Somasundaram K
Cell Biol Toxicol; 2020 Jun; 36(3):273-278. PubMed ID: 31758290
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Nam Y; Koo H; Yang Y; Shin S; Zhu Z; Kim D; Cho HJ; Mu Q; Choi SW; Sa JK; Seo YJ; Kim Y; Lee K; Oh JW; Kwon YJ; Park WY; Kong DS; Seol HJ; Lee JI; Park CK; Lee HW; Yoon Y; Wang J
Genome Med; 2023 Mar; 15(1):16. PubMed ID: 36915208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
